Astrazeneca Plc ADR (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Sales | 11,416,000 | 10,879,000 | 11,208,000 | 10,982,000 | 10,771,000 |
| Cost of Goods | 1,960,000 | 1,905,000 | 2,900,000 | 2,982,000 | 2,998,000 |
| Gross Profit | 9,456,000 | 8,974,000 | 8,308,000 | 8,000,000 | 7,773,000 |
| Operating Expenses | 7,000,000 | 6,425,000 | 7,213,000 | 6,755,000 | 7,234,000 |
| Operating Income | 2,456,000 | 2,549,000 | 1,095,000 | 1,245,000 | 539,000 |
| Interest Expense | 431,000 | 365,000 | 360,000 | 339,000 | 311,000 |
| Other Income | 63,000 | 78,000 | 44,000 | 16,000 | 19,000 |
| Pre-tax Income | 2,088,000 | 2,262,000 | 779,000 | 922,000 | 247,000 |
| Income Tax | 268,000 | 458,000 | -124,000 | -720,000 | -113,000 |
| Net Income Continuous | 1,820,000 | 1,804,000 | 903,000 | 1,642,000 | 360,000 |
| Minority Interests | 2,000 | N/A | 1,000 | 2,000 | N/A |
| Net Income | $1,818,000 | $1,804,000 | $902,000 | $1,640,000 | $360,000 |
| EPS Basic Total Ops | 0.59 | 0.58 | 0.29 | 0.53 | 0.12 |
| EPS Basic Continuous Ops | 0.59 | 0.58 | 0.29 | 0.53 | 0.12 |
| EPS Diluted Total Ops | 0.59 | 0.58 | 0.29 | 0.53 | 0.12 |
| EPS Diluted Continuous Ops | 0.58 | 0.58 | 0.29 | 0.53 | 0.12 |
| EPS Diluted Before Non-Recurring Items | 1.08 | 0.96 | 0.69 | N/A | N/A |
| EBITDA(a) | $3,732,000 | $4,051,000 | $2,575,000 | $2,579,000 | $1,896,000 |